ISPOR PUBLISHES TASK FORCE REPORT #2 ON MULTIPLE CRITERIA DECISION ANALYSIS

Published Apr 5, 2016

Second Report Published in March/April Issue of Value in Health

Princeton, NJ—April 5, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) published a new Task Force Report, “Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force, ” in the March/April 2016 issue of Value in Health.  Many health care decisions are complex and require consideration of multiple, often conflicting objectives. They involve trade-offs that decision makers find challenging or on which they disagree. For instance, regulators often have to assess whether the benefits of a drug are sufficient to accept its safety risks. Lead author Kevin Marsh stated, “Decision makers, whether they are individuals, payers, or health ministries, often have difficulty processing and systematically evaluating potential treatment options and the numerous disparate factors impacting them. This set of techniques known as multiple criteria decision analysis (MCDA) can significantly improve the quality of complicated health care decisions.” This second MCDA Task Force Report builds on the foundational Report #1, “Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force,” published in the January/February 2016 issue of Value in Health. Co-author Maarten IJzerman explained, “While many MCDA methods exist, there is currently insufficient guidance on how to choose the right technique for a specific health care issue. The good practice guidelines provide an overview of the available MCDA methods and the principles to apply in choosing an appropriate method for a particular problem or decision.” The Task Force also developed a valuable checklist, the ISPOR MCDA Good Practice Guidelines Checklist, that outlines the steps for implementing MCDA. Finally, the capacity of MCDA to incorporate patients’ preferences on benefits and trade-offs of treatment options is an important benefit to all stakeholders.

###

Related Stories

International Study Confirms Universally Applicable Framework for Defining Digital Health Interventions

Jan 21, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a comprehensive international study demonstrating that the PICOTS-ComTeC framework serves as an effective universal standard for defining patient-facing digital health interventions. The report, “Towards a Common Ground for Defining Digital Health Interventions, Mapping Digital Health Frameworks to PICOTS-ComTeC: An ISPOR Special Interest Group Report” was published in the January 2026 issue of Value in Health.

New Research Collection Reveals How Artificial Intelligence Is Reshaping Health Economics

Nov 6, 2025

The PhRMA Foundation and ISPOR announced the publication of a special themed section of research papers that explores the dynamic intersection of artificial intelligence (AI) and health economics and outcomes research (HEOR).

ISPOR Announces 2025 Health Economics and Outcomes Research Award Honorees

Oct 20, 2025

ISPOR announced the recipients of its 2025 Health Economics and Outcomes Research (HEOR) Scientific and Leadership Awards. ISPOR Scientific Awards are designed to foster and recognize excellence and outstanding achievement in HEOR and its Leadership Awards recognize excellence and outstanding leadership in the field.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×